Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 53.9x - 59.5x | 56.7x |
| Selected Fwd P/E Multiple | 33.7x - 37.3x | 35.5x |
| Fair Value | ₩5,013 - ₩5,541 | ₩5,277 |
| Upside | -4.1% - 5.9% | 0.9% |
| Benchmarks | - | Full Ticker |
| JW Lifescience Corporation | - | KOSE:A234080 |
| Kyung Dong Pharmaceutical Co., Ltd. | - | KOSDAQ:A011040 |
| Ahn-Gook Pharmaceutical Co., Ltd. | - | KOSDAQ:A001540 |
| Dongwha Pharm.Co.,Ltd | - | KOSE:A000020 |
| Ilyang Pharmaceutical Co.,Ltd | - | KOSE:A007570 |
| DongKoo Bio & Pharma Co., Ltd. | - | KOSDAQ:A006620 |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| A234080 | A011040 | A001540 | A000020 | A007570 | A006620 | |||
| KOSE:A234080 | KOSDAQ:A011040 | KOSDAQ:A001540 | KOSE:A000020 | KOSE:A007570 | KOSDAQ:A006620 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 14.9% | -22.9% | 46.0% | -9.4% | 0.5% | NM- | ||
| 3Y CAGR | 50.5% | -24.4% | 62.3% | -32.2% | -9.9% | -39.8% | ||
| Latest Twelve Months | 56.3% | 126.4% | 1205.7% | -79.7% | 525.9% | -82.8% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 10.4% | 3.3% | 2.2% | 6.8% | 4.6% | 4.8% | ||
| Prior Fiscal Year | 13.6% | -12.7% | 0.6% | 7.6% | -0.9% | 5.5% | ||
| Latest Fiscal Year | 19.8% | 2.8% | 6.2% | 1.2% | 3.8% | 0.8% | ||
| Latest Twelve Months | 19.8% | 2.8% | 6.2% | 1.2% | 3.8% | 0.8% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 4.5x | 10.9x | 6.5x | 5.6x | 11.5x | 7.1x | ||
| Price / LTM Sales | 0.8x | 0.8x | 0.3x | 0.4x | 0.7x | 0.6x | ||
| LTM P/E Ratio | 3.9x | 27.2x | 4.4x | 29.9x | 17.9x | 69.5x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | 3.9x | 17.9x | 29.9x | |||||
| Historical LTM P/E Ratio | 20.2x | 27.1x | 69.5x | |||||
| Selected P/E Multiple | 53.9x | 56.7x | 59.5x | |||||
| (x) LTM Net Income | 2,036 | 2,036 | 2,036 | |||||
| (=) Equity Value | 109,663 | 115,435 | 121,206 | |||||
| (/) Shares Outstanding | 27.0 | 27.0 | 27.0 | |||||
| Implied Value Range | 4,055.26 | 4,268.70 | 4,482.13 | |||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 4,055.26 | 4,268.70 | 4,482.13 | 5,230.00 | ||||
| Upside / (Downside) | -22.5% | -18.4% | -14.3% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | A234080 | A011040 | A001540 | A000020 | A007570 | A006620 | |
| Value of Common Equity | 172,033 | 148,988 | 73,989 | 166,585 | 183,737 | 141,430 | |
| (/) Shares Outstanding | 15.5 | 26.9 | 11.4 | 27.7 | 18.0 | 27.0 | |
| Implied Stock Price | 11,110.00 | 5,530.00 | 6,510.00 | 6,010.00 | 10,200.00 | 5,230.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 11,110.00 | 5,530.00 | 6,510.00 | 6,010.00 | 10,200.00 | 5,230.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |